Intra-cellular Therapies Stock News

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:40 am ET.

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.

Elemental Advisors Inc. has launched its first ETF, composed of companies involved in research, development, production or use of psychedelics to address medical conditions. The PSYK ETF (NYSE: PSYK)

A new thematic ETF providing exposure to the medicinal psychedelic drug industry, PSYK ETF, has just been launched.

Stocks Analysis by Zacks Investment Research covering: Intracellular Th. Read Zacks Investment Research''s latest article on Investing.com

Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down

Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down

Intra-Cellular Therapies <> has bounced back from a one-month low as several Wall Street analysts pointed to the strong performance of the companys antipsychotic

Intra-Cellular Therapies <> has gained more than a tenth even after its Chief Medical Officer Suresh Durgam declared the sale of more than a fifth of his holdings at the company.In

Intra-Cellular Therapies Inc (ITCI) shares closed this week 21.2% lower than it did at the end of last week. The stock is currently down 21.7% year-to-date, up 24.4% over the past 12 months, and up 147.7% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Shares traded as high as $47.98 and as low as $39.50 this week.Shares closed 26.8% below its 52-week high and 42.2% above its 52-week low.Trading volume this week was 37.2% lower than the 10-day average and 5.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 89.3% The company's stock price performance over the past 12 months beats the peer average by -147.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central n

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central n